Christy Cassarly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christy Cassarly has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Joseph P. Broderick
Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH
4 shared publications - David L. Tirschwell
Department of Neurology, University of Washington, Seattle, Washington, USA
3 shared publications Edsel A. Peña
D Department of Statistics , University of South Carolina , Columbia , SC , USA
3 shared publications- Hooman Kamel
Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology Weill Cornell Medicine New York NY
3 shared publications Julius Fridriksson
Univ South Carolina, Dept Commun Sci & Disorders, Columbia, SC USA
3 shared publications- Maarten G. Lansberg
Department of Neurology, Stanford University, CA (M.G.L., G.W.A.).
3 shared publications
Latest Publications
- 8 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2510-2519
Transcranial Direct Current Stimulation for Stroke Motor Recovery What the TRANSPORT2 Trial Taught Us
Over the past 2 decades, transcranial direct current stimulation has attracted substantial interest as an adjunctive strategy to enhance poststroke motor recovery. In addition to its potential neuromodulatory effects on motor cortical networks, transcranial direct current stimulation devices are low-cost, easy to use, and compatible with concurrent rehabilitation. Yet, despite its promise, several barriers hinder translation into routine clinical practice, including neutral results from several recently completed multicenter trials, such as TRANSPORT2 (Transcranial Direct Current Stimulation for Post-Stroke Motor Recovery). Moving forward, progress will depend on addressing issues in 3 broad domains: device-related (stimulation parameters and montage), disease-related (patient characteristics and timing), and trial design (outcomes, analytical approaches, adjunctive therapy, and trial infrastructure). In this topical review, we critically examine these challenges and outline strategies to refine transcranial direct current stimulation application, with the goal of more effectively leveraging its neuromodulation properties to promote neuroplasticity and enhance motor recovery after stroke.
- 8 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2510-2519
Transcranial Direct Current Stimulation for Stroke Motor Recovery What the TRANSPORT2 Trial Taught Us
Over the past 2 decades, transcranial direct current stimulation has attracted substantial interest as an adjunctive strategy to enhance poststroke motor recovery. In addition to its potential neuromodulatory effects on motor cortical networks, transcranial direct current stimulation devices are low-cost, easy to use, and compatible with concurrent rehabilitation. Yet, despite its promise, several barriers hinder translation into routine clinical practice, including neutral results from several recently completed multicenter trials, such as TRANSPORT2 (Transcranial Direct Current Stimulation for Post-Stroke Motor Recovery). Moving forward, progress will depend on addressing issues in 3 broad domains: device-related (stimulation parameters and montage), disease-related (patient characteristics and timing), and trial design (outcomes, analytical approaches, adjunctive therapy, and trial infrastructure). In this topical review, we critically examine these challenges and outline strategies to refine transcranial direct current stimulation application, with the goal of more effectively leveraging its neuromodulation properties to promote neuroplasticity and enhance motor recovery after stroke.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 570-576
Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial
BACKGROUND: In patients with cryptogenic stroke, the characteristics of multiterritory brain infarcts, the recurrent stroke risk, and the response to anticoagulation remain unclear. METHODS: The ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) screened patients with cryptogenic stroke for atrial cardiopathy at 185 centers in the United States and Canada from 2018 to 2022. Investigators reported baseline acute brain infarction in the left anterior, right anterior, and posterior circulation. Atrial cardiopathy was defined as P-wave terminal force in ECG lead V1s >5000 μV·ms, NT-proBNP (N-terminal pro-B-type natriuretic peptide) >250 pg/mL, or left atrial diameter index ≥3 cm/m 2 . Site echocardiography laboratories determined left atrial diameter index and a central echocardiography laboratory determined LVEF. We used ANCOVA to examine whether atrial cardiopathy biomarkers or LVEF were associated with the number of territories with infarction. Cox regression was used to examine whether the number of infarct territories was associated with recurrent stroke or modified the effect of apixaban compared with aspirin. RESULTS: Among 3464 patients with reported baseline magnetic resonance imaging data, 220 (6.4%) had no visible acute infarct and 2794 (80.7%) had acute infarction in 1, 374 (10.8%) in 2, and 76 (2.2%) in 3 territories. Atrial cardiopathy biomarkers and LVEF were not associated with the number of infarct territories. Among 937 of these 3464 patients who were randomized, we found higher risks of recurrent stroke associated with infarcts in 2 territories (hazard ratio, 2.4 [95% CI, 1.3–4.2]) or 3 territories (hazard ratio, 3.7 [95% CI, 1.5–9.3]) relative to single-territory infarction, whereas the absence of visible infarction was not associated with recurrence (hazard ratio, 1.8 [95% CI, 0.6–4.9]). The number of infarct territories did not modify the effect of apixaban versus aspirin in relation to recurrent stroke ( P for interaction, 0.71). CONCLUSIONS: Multiterritory brain infarction was not associated with atrial cardiopathy biomarkers or LVEF in the ARCADIA trial. Multiterritory infarction was associated with a significantly higher risk of recurrent stroke, but this heightened risk was not reduced by apixaban relative to aspirin.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 570-576
Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial
BACKGROUND: In patients with cryptogenic stroke, the characteristics of multiterritory brain infarcts, the recurrent stroke risk, and the response to anticoagulation remain unclear. METHODS: The ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) screened patients with cryptogenic stroke for atrial cardiopathy at 185 centers in the United States and Canada from 2018 to 2022. Investigators reported baseline acute brain infarction in the left anterior, right anterior, and posterior circulation. Atrial cardiopathy was defined as P-wave terminal force in ECG lead V1s >5000 μV·ms, NT-proBNP (N-terminal pro-B-type natriuretic peptide) >250 pg/mL, or left atrial diameter index ≥3 cm/m 2 . Site echocardiography laboratories determined left atrial diameter index and a central echocardiography laboratory determined LVEF. We used ANCOVA to examine whether atrial cardiopathy biomarkers or LVEF were associated with the number of territories with infarction. Cox regression was used to examine whether the number of infarct territories was associated with recurrent stroke or modified the effect of apixaban compared with aspirin. RESULTS: Among 3464 patients with reported baseline magnetic resonance imaging data, 220 (6.4%) had no visible acute infarct and 2794 (80.7%) had acute infarction in 1, 374 (10.8%) in 2, and 76 (2.2%) in 3 territories. Atrial cardiopathy biomarkers and LVEF were not associated with the number of infarct territories. Among 937 of these 3464 patients who were randomized, we found higher risks of recurrent stroke associated with infarcts in 2 territories (hazard ratio, 2.4 [95% CI, 1.3–4.2]) or 3 territories (hazard ratio, 3.7 [95% CI, 1.5–9.3]) relative to single-territory infarction, whereas the absence of visible infarction was not associated with recurrence (hazard ratio, 1.8 [95% CI, 0.6–4.9]). The number of infarct territories did not modify the effect of apixaban versus aspirin in relation to recurrent stroke ( P for interaction, 0.71). CONCLUSIONS: Multiterritory brain infarction was not associated with atrial cardiopathy biomarkers or LVEF in the ARCADIA trial. Multiterritory infarction was associated with a significantly higher risk of recurrent stroke, but this heightened risk was not reduced by apixaban relative to aspirin.
- Open Access
- 22 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (18) , e042147
Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA‐Cognition Study
Background: ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a secondary stroke prevention study comparing apixaban versus aspirin for cryptogenic stroke and biomarkers of atrial cardiopathy, ended prematurely for futility. In the ARCADIA‐Cognition study we hypothesized that cognitive decline would be slower in the apixaban arm due to less microembolization. Methods: ARCADIA subjects on study drug and eligible for magnetic resonance imaging participated in ARCADIA‐CSI (ARCADIA‐Cognition and Silent Infarction). Cognitive tests were administered centrally by telephone ≥3 months after the ARCADIA index stroke and yearly thereafter. Composite Z scores were the means of 5 standardized cognitive tests. Trajectories of the composite Z score and the individual test scores were compared between treatment arms using a mixed‐effects model. Results: Of 799 screened patients at 75 sites, 310 were enrolled in ARCADIA‐CSI. Of these, 296 completed at least 1 cognitive exam, and 47 subjects were excluded from the primary analysis for baseline dementia. For the 249 subjects included in the analysis, there were 582 cognitive assessments. Baseline characteristics were balanced between the apixaban (n=128) and aspirin (n=121) arms. Mean age was 68 (SD: 10.4) years, median modified Rankin Scale score 1 (interquartile range, 0–2), 52% female, and 19% Black. During median follow‐up of 378 (interquartile range, 183–735) days, the annual change in the overall standardized composite score was 0.084 (95% CI, 0.017–0.149) in the aspirin arm and 0.107 (95% CI, 0.041–0.174) in the apixaban arm ( P =0.62). Conclusions: Cognitive trajectories did not differ between apixaban and aspirin. Further studies should address infarct location and volume and concurrent pathology to determine optimal treatment to mitigate cognitive decline with atrial disease. Registration: URL: http://clinicaltrials.gov ; Unique Identifier: NCT03192215.
- 22 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (18) , e042147
Open AccessApixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA‐Cognition Study
Background: ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a secondary stroke prevention study comparing apixaban versus aspirin for cryptogenic stroke and biomarkers of atrial cardiopathy, ended prematurely for futility. In the ARCADIA‐Cognition study we hypothesized that cognitive decline would be slower in the apixaban arm due to less microembolization. Methods: ARCADIA subjects on study drug and eligible for magnetic resonance imaging participated in ARCADIA‐CSI (ARCADIA‐Cognition and Silent Infarction). Cognitive tests were administered centrally by telephone ≥3 months after the ARCADIA index stroke and yearly thereafter. Composite Z scores were the means of 5 standardized cognitive tests. Trajectories of the composite Z score and the individual test scores were compared between treatment arms using a mixed‐effects model. Results: Of 799 screened patients at 75 sites, 310 were enrolled in ARCADIA‐CSI. Of these, 296 completed at least 1 cognitive exam, and 47 subjects were excluded from the primary analysis for baseline dementia. For the 249 subjects included in the analysis, there were 582 cognitive assessments. Baseline characteristics were balanced between the apixaban (n=128) and aspirin (n=121) arms. Mean age was 68 (SD: 10.4) years, median modified Rankin Scale score 1 (interquartile range, 0–2), 52% female, and 19% Black. During median follow‐up of 378 (interquartile range, 183–735) days, the annual change in the overall standardized composite score was 0.084 (95% CI, 0.017–0.149) in the aspirin arm and 0.107 (95% CI, 0.041–0.174) in the apixaban arm ( P =0.62). Conclusions: Cognitive trajectories did not differ between apixaban and aspirin. Further studies should address infarct location and volume and concurrent pathology to determine optimal treatment to mitigate cognitive decline with atrial disease. Registration: URL: http://clinicaltrials.gov ; Unique Identifier: NCT03192215.
- 6 August 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (2) , 322-328
MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial
BACKGROUND AND PURPOSE: The ARCADIA-MRI study, an ancillary study to the randomized Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, reported that the risk of incident non-lacunar covert infarcts was lower in the apixaban group than the aspirin group. This paper presents the additional, prespecified, exploratory outcomes beyond the primary paper, specifically examining the effect of apixaban on hemorrhagic lesions on MRI. MATERIALS AND METHODS: The ARCADIA-MRI study was conducted in conjunction with ARCADIA trial visits, with follow-up durations ranging from 4 months to 5.3 years (median 27 months). It included randomized patients who were eligible for cognitive testing and lacked MRI contraindications. Two experienced raters, blinded to treatment assignments, independently evaluated the baseline and follow-up MRI scans. The radiological endpoints of this analysis were incident intracerebral hemorrhages (>10 mm), microbleeds (≤10 mm), and superficial siderosis. RESULTS: MRI outcomes were compared between the 79 patients in the apixaban group and 95 in the aspirin group with both baseline and follow-up MRIs available. The treatment groups had similar baseline MRI findings. On the follow-up MRIs, the findings of incident bleeding events were all similar between the treatment groups (all p > 0.05): intracerebral hemorrhages occurred in 5.1% of patients in the apixaban group compared to 6.4% of patients in the aspirin group; microbleeds, 7.8% in the apixaban group and 10.8% in the aspirin group; and cortical superficial siderosis, in 7.7% of apixaban group and 12.9% in the aspirin group. CONCLUSIONS: In an exploratory analysis of the ARCADIA-MRI substudy, MRI findings of incident bleeding events were similar in patients randomized to receive apixaban and aspirin. ABBREVIATIONS: ARCADIA= atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke; AF= atrial fibrillation; DOAC= direct-acting oral anticoagulants; ICH =intracerebral hemorrhage; NT-proBNP= N-terminal pro–B-type natriuretic peptide; NAVIGATE ESUS=Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source; RE-SPECT ESUS=Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source; COMPASS =Cardiovascular Outcomes for People Using Anticoagulation Strategies; ATTICUS study =The Apixaban for Treatment of Embolic Stroke of Undetermined Source.
- 6 August 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (2) , 322-328
MRI Findings of Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial
BACKGROUND AND PURPOSE: The ARCADIA-MRI study, an ancillary study to the randomized Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, reported that the risk of incident non-lacunar covert infarcts was lower in the apixaban group than the aspirin group. This paper presents the additional, prespecified, exploratory outcomes beyond the primary paper, specifically examining the effect of apixaban on hemorrhagic lesions on MRI. MATERIALS AND METHODS: The ARCADIA-MRI study was conducted in conjunction with ARCADIA trial visits, with follow-up durations ranging from 4 months to 5.3 years (median 27 months). It included randomized patients who were eligible for cognitive testing and lacked MRI contraindications. Two experienced raters, blinded to treatment assignments, independently evaluated the baseline and follow-up MRI scans. The radiological endpoints of this analysis were incident intracerebral hemorrhages (>10 mm), microbleeds (≤10 mm), and superficial siderosis. RESULTS: MRI outcomes were compared between the 79 patients in the apixaban group and 95 in the aspirin group with both baseline and follow-up MRIs available. The treatment groups had similar baseline MRI findings. On the follow-up MRIs, the findings of incident bleeding events were all similar between the treatment groups (all p > 0.05): intracerebral hemorrhages occurred in 5.1% of patients in the apixaban group compared to 6.4% of patients in the aspirin group; microbleeds, 7.8% in the apixaban group and 10.8% in the aspirin group; and cortical superficial siderosis, in 7.7% of apixaban group and 12.9% in the aspirin group. CONCLUSIONS: In an exploratory analysis of the ARCADIA-MRI substudy, MRI findings of incident bleeding events were similar in patients randomized to receive apixaban and aspirin. ABBREVIATIONS: ARCADIA= atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke; AF= atrial fibrillation; DOAC= direct-acting oral anticoagulants; ICH =intracerebral hemorrhage; NT-proBNP= N-terminal pro–B-type natriuretic peptide; NAVIGATE ESUS=Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source; RE-SPECT ESUS=Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source; COMPASS =Cardiovascular Outcomes for People Using Anticoagulation Strategies; ATTICUS study =The Apixaban for Treatment of Embolic Stroke of Undetermined Source.
- Open Access
- 28 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 42, 101406
TEleRehabilitation foR Aphasia (TERRA) phase II trial design
- 28 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 42, 101406
Open AccessTEleRehabilitation foR Aphasia (TERRA) phase II trial design
- 14 August 2024
- Published by Springer Nature
- p. 289-311
Maximum Tolerated Imbalance Randomization: Theory and Practice
- 14 August 2024
- Published by Springer Nature
- p. 289-311
Maximum Tolerated Imbalance Randomization: Theory and Practice
- 20 January 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (6) , 1194-1212
Steady‐state statistical properties and implementation of randomization designs with maximum tolerated imbalance restriction for two‐arm equal allocation clinical trials
In recent decades, several randomization designs have been proposed in the literature as better alternatives to the traditional permuted block design (PBD), providing higher allocation randomness under the same restriction of the maximum tolerated imbalance (MTI). However, PBD remains the most frequently used method for randomizing subjects in clinical trials. This status quo may reflect an inadequate awareness and appreciation of the statistical properties of these randomization designs, and a lack of simple methods for their implementation. This manuscript presents the analytic results of statistical properties for five randomization designs with MTI restriction based on their steady‐state probabilities of the treatment imbalance Markov chain and compares them to those of the PBD. A unified framework for randomization sequence generation and real‐time on‐demand treatment assignment is proposed for the straightforward implementation of randomization algorithms with explicit formulas of conditional allocation probabilities. Topics associated with the evaluation, selection, and implementation of randomization designs are discussed. It is concluded that for two‐arm equal allocation trials, several randomization designs offer stronger protection against selection bias than the PBD does, and their implementation is not necessarily more difficult than the implementation of the PBD.
- 20 January 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (6) , 1194-1212
Steady‐state statistical properties and implementation of randomization designs with maximum tolerated imbalance restriction for two‐arm equal allocation clinical trials
In recent decades, several randomization designs have been proposed in the literature as better alternatives to the traditional permuted block design (PBD), providing higher allocation randomness under the same restriction of the maximum tolerated imbalance (MTI). However, PBD remains the most frequently used method for randomizing subjects in clinical trials. This status quo may reflect an inadequate awareness and appreciation of the statistical properties of these randomization designs, and a lack of simple methods for their implementation. This manuscript presents the analytic results of statistical properties for five randomization designs with MTI restriction based on their steady‐state probabilities of the treatment imbalance Markov chain and compares them to those of the PBD. A unified framework for randomization sequence generation and real‐time on‐demand treatment assignment is proposed for the straightforward implementation of randomization algorithms with explicit formulas of conditional allocation probabilities. Topics associated with the evaluation, selection, and implementation of randomization designs are discussed. It is concluded that for two‐arm equal allocation trials, several randomization designs offer stronger protection against selection bias than the PBD does, and their implementation is not necessarily more difficult than the implementation of the PBD.
- 1 July 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (7) , 1909-1919
Optimal Randomization Designs for Large Multicenter Clinical Trials: From the National Institutes of Health Stroke Trials Network Funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke Experience
From 2016 to 2021, the National Institutes of Health Stroke Trials Network funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke initiated ten multicenter randomized controlled clinical trials. Optimal subject randomization designs are demanded with 4 critical properties: (1) protection of treatment assignment randomness, (2) achievement of the desired treatment allocation ratio, (3) balancing of baseline covariates, and (4) ease of implementation. For acute stroke trials, it is necessary to minimize the time between eligibility assessment and treatment initiation. This article reviews the randomization designs for 3 trials currently enrolling in Stroke Trials Network funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke, the SATURN (Statins in Intracerebral Hemorrhage Trial), the MOST (Multiarm Optimization of Stroke Thrombolysis Trial), and the FASTEST (Recombinant Factor VIIa for Hemorrhagic Stroke Trial). Randomization methods utilized in these trials include minimal sufficient balance, block urn design, big stick design, and step-forward randomization. Their advantages and limitations are reviewed and compared with traditional stratified permuted block design and minimization.
- 1 July 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (7) , 1909-1919
Optimal Randomization Designs for Large Multicenter Clinical Trials: From the National Institutes of Health Stroke Trials Network Funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke Experience
From 2016 to 2021, the National Institutes of Health Stroke Trials Network funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke initiated ten multicenter randomized controlled clinical trials. Optimal subject randomization designs are demanded with 4 critical properties: (1) protection of treatment assignment randomness, (2) achievement of the desired treatment allocation ratio, (3) balancing of baseline covariates, and (4) ease of implementation. For acute stroke trials, it is necessary to minimize the time between eligibility assessment and treatment initiation. This article reviews the randomization designs for 3 trials currently enrolling in Stroke Trials Network funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke, the SATURN (Statins in Intracerebral Hemorrhage Trial), the MOST (Multiarm Optimization of Stroke Thrombolysis Trial), and the FASTEST (Recombinant Factor VIIa for Hemorrhagic Stroke Trial). Randomization methods utilized in these trials include minimal sufficient balance, block urn design, big stick design, and step-forward randomization. Their advantages and limitations are reviewed and compared with traditional stratified permuted block design and minimization.
- 1 April 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (4) , 912-920
Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled Trial
Background: Transcranial direct-current stimulation (tDCS) is a promising adjunct to therapy for chronic aphasia. Methods: This single-center, randomized, double-blind, sham-controlled efficacy trial tested the hypothesis that anodal tDCS augments language therapy in subacute aphasia. Secondarily, we compared the effect of tDCS on discourse measures and quality of life and compared the effects on naming to previous findings in chronic stroke. Right-handed English speakers with aphasia <3 months after left hemisphere ischemic stroke were included, unless they had prior neurological or psychiatric disease or injury or were taking certain medications (34 excluded; final sample, 58). Participants were randomized 1:1, controlling for age, aphasia type, and severity, to receive 20 minutes of tDCS (1 mA) or sham-tDCS in addition to fifteen 45-minute sessions of naming treatment (plus standard care). The primary outcome variable was change in naming accuracy of untrained pictures pretreatment to 1-week posttreatment. Results: Baseline characteristics were similar between the tDCS (N=30) and sham (N=28) groups: patients were 65 years old, 53% male, and 2 months from stroke onset on average. In intent-to-treat analysis, the adjusted mean change from baseline to 1-week posttreatment in picture naming was 22.3 (95% CI, 13.5–31.2) for tDCS and 18.5 (9.6–27.4) for sham and was not significantly different. Content and efficiency of picture description improved more with tDCS than sham. Groups did not differ in quality of life improvement. No patients were withdrawn due to adverse events. Conclusions: tDCS did not improve recovery of picture naming but did improve recovery of discourse. Discourse skills are critical to participation. Future research should examine tDCS in a larger sample with richer functional outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02674490.
- 1 April 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (4) , 912-920
Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled Trial
Background: Transcranial direct-current stimulation (tDCS) is a promising adjunct to therapy for chronic aphasia. Methods: This single-center, randomized, double-blind, sham-controlled efficacy trial tested the hypothesis that anodal tDCS augments language therapy in subacute aphasia. Secondarily, we compared the effect of tDCS on discourse measures and quality of life and compared the effects on naming to previous findings in chronic stroke. Right-handed English speakers with aphasia <3 months after left hemisphere ischemic stroke were included, unless they had prior neurological or psychiatric disease or injury or were taking certain medications (34 excluded; final sample, 58). Participants were randomized 1:1, controlling for age, aphasia type, and severity, to receive 20 minutes of tDCS (1 mA) or sham-tDCS in addition to fifteen 45-minute sessions of naming treatment (plus standard care). The primary outcome variable was change in naming accuracy of untrained pictures pretreatment to 1-week posttreatment. Results: Baseline characteristics were similar between the tDCS (N=30) and sham (N=28) groups: patients were 65 years old, 53% male, and 2 months from stroke onset on average. In intent-to-treat analysis, the adjusted mean change from baseline to 1-week posttreatment in picture naming was 22.3 (95% CI, 13.5–31.2) for tDCS and 18.5 (9.6–27.4) for sham and was not significantly different. Content and efficiency of picture description improved more with tDCS than sham. Groups did not differ in quality of life improvement. No patients were withdrawn due to adverse events. Conclusions: tDCS did not improve recovery of picture naming but did improve recovery of discourse. Discourse skills are critical to participation. Future research should examine tDCS in a larger sample with richer functional outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02674490.